Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy

A Delicate Balance - The BCL-2 Family and its Role in Apoptosis, Oncogenesis, and Cancer Therapeutics

(2019) Tristan Knight et al.   BIOCHEMICAL PHARMACOLOGY

Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment

(2019) Wang Manni et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Therapeutic advances in hormone-dependent cancers: focus on prostate, breast, and ovarian cancers

(2019) Michael Ulm et al.   Endocrine Connections

Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells

(2019) Anna Wawruszak et al.   Cancers

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

(2018) Chaoyang Sun et al.   CANCER CELL

BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC

(2018) Brandon Leonard et al.   CANCER RESEARCH

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

TargetingHER2Aberrations in Non–Small Cell Lung Cancer with Osimertinib

(2018) Shengwu Liu et al.   CLINICAL CANCER RESEARCH

Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma

(2018) Yiru Zhang et al.   CLINICAL CANCER RESEARCH

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

(2018) Ileabett M Echevarría‐Vargas et al.   EMBO Molecular Medicine

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma

(2018) Sara Bolin et al.   ONCOGENE

Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors

(2018) Xiulan Lai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells

(2018) Karin Bauer et al.   Oncotarget

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer

(2018) Aishwarya Pawar et al.   Cell Reports

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer

(2018) Xiangyi Li et al.   Cell Reports

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

(2018) Alexander S. Hölscher et al.   Clinical Epigenetics

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

(2018) Anastasia Wyce et al.   Oncogenesis

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

(2018) Amila Suraweera et al.   Frontiers in Oncology

BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy

(2018) C. Mio et al.   INTERNATIONAL JOURNAL OF CANCER

Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry

(2018) Adam D. Durbin et al.   NATURE GENETICS

Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma

(2018) K. Tomska et al.   Scientific Reports

Effects of novel HDAC inhibitors on urothelial carcinoma cells

(2018) Aline Kaletsch et al.   Clinical Epigenetics

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response inKras-Mutant Non–Small Cell Lung Cancer

(2018) Dennis O. Adeegbe et al.   Cancer Immunology Research

Receptor Tyrosine Kinase-Targeted Cancer Therapy

(2018) Toshimitsu Yamaoka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

BRD4 and Cancer: going beyond transcriptional regulation

(2018) Benedetta Donati et al.   Molecular Cancer

Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation

(2018) Sang Park et al.   ONCOLOGY REPORTS

Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer

(2018) Anna C. Ferrari et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia

(2017) S Peirs et al.   LEUKEMIA

Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response

(2017) J Long et al.   LEUKEMIA

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

(2017) John K. Simmons et al.   MOLECULAR CANCER THERAPEUTICS

Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors

(2017) Lloyd T. Lam et al.   MOLECULAR CANCER THERAPEUTICS

BRD4 inhibitors block telomere elongation

(2017) Steven Wang et al.   NUCLEIC ACIDS RESEARCH

RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN

(2017) Valentina Sancisi et al.   NUCLEIC ACIDS RESEARCH

Inhibitors of cyclin-dependent kinases as cancer therapeutics

(2017) Steven R. Whittaker et al.   PHARMACOLOGY & THERAPEUTICS

Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

(2017) Lu Yang et al.   Science Translational Medicine

mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors

(2017) Clare F. Malone et al.   Cancer Discovery

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma

(2017) Chiaki Tsuge Ishida et al.   Oncotarget

Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors

(2017) Natalia Moreno et al.   Oncotarget

HDAC inhibitors enhance the immunotherapy response of melanoma cells

(2017) Laurence Booth et al.   Oncotarget

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence

(2017) Katherine R. Singleton et al.   Cell Reports

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent

(2017) Beverly A. Teicher et al.   Cancer Medicine

JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells

(2017) Ilaria Zanellato et al.   CURRENT CANCER DRUG TARGETS

Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors

(2016) Zhimin Zhang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer

(2016) Yuhki Yokoyama et al.   CANCER RESEARCH

The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects

(2016) J. Shahbazi et al.   CLINICAL CANCER RESEARCH

The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer

(2016) Yufang Ma et al.   CLINICAL CANCER RESEARCH

MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance

(2016) Nora Rauch et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer

(2016) Mark L. McCleland et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas

(2016) Wenyin Shi et al.   JOURNAL OF NEURO-ONCOLOGY

Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer

(2016) Emily Chan et al.   RADIOTHERAPY AND ONCOLOGY

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents

(2016) Olaf Klingbeil et al.   Cell Death & Disease

Histone deacetylase inhibitors as immunomodulators in cancer therapeutics

(2016) Li Shen et al.   Epigenomics

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

(2016) Ramiro Vázquez et al.   Oncotarget

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

(2016) Haeseong Park et al.   Oncotarget

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

(2016) Eugenio Gaudio et al.   Oncotarget

High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML

(2016) Yue Zhao et al.   Cell Reports

BET and BRAF inhibitors act synergistically againstBRAF-mutant melanoma

(2016) Luca Paoluzzi et al.   Cancer Medicine

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

(2016) Céline Berthon et al.   Lancet Haematology

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement

(2015) Surojeet Sengupta et al.   BREAST CANCER RESEARCH AND TREATMENT

Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2

(2015) V. Sancisi et al.   CANCER RESEARCH

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

(2015) M. Boi et al.   CLINICAL CANCER RESEARCH

A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma

(2015) Yoshiaki Ogawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors

(2015) Matthew Zibelman et al.   INVESTIGATIONAL NEW DRUGS

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

(2015) David E. Gerber et al.   LUNG CANCER

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy

(2015) C. Xu et al.   MOLECULAR CANCER THERAPEUTICS

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

(2015) Pawel K Mazur et al.   NATURE MEDICINE

Protein acetylation in metabolism — metabolites and cofactors

(2015) Keir J. Menzies et al.   Nature Reviews Endocrinology

Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function

(2015) Sophia Pinz et al.   NUCLEIC ACIDS RESEARCH

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

(2015) K Cao et al.   ONCOGENE

Concomitant BET and MAPK blockade for effective treatment of ovarian cancer

(2015) Ying Jing et al.   Oncotarget

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

(2015) Anja Heinemann et al.   Oncotarget

BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells

(2015) Emma K Baker et al.   Scientific Reports

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

(2015) Timothy J. Stuhlmiller et al.   Cell Reports

Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery

(2015) Celeste B. Greer et al.   Cell Reports

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)

(2014) Antonio Avallone et al.   BMC CANCER

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

(2014) Qin Feng et al.   CELL RESEARCH

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors

(2014) J. E. Gray et al.   CLINICAL CANCER RESEARCH

Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism

(2014) Kwai Fung Hui et al.   INTERNATIONAL JOURNAL OF CANCER

Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma

(2014) Dhong Hyun Lee et al.   INTERNATIONAL JOURNAL OF CANCER

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors

(2014) Nuttapong Ngamphaiboon et al.   INVESTIGATIONAL NEW DRUGS

Histone Cross-talk Connects Protein Phosphatase 1α (PP1α) and Histone Deacetylase (HDAC) Pathways to Regulate the Functional Transition of Bromodomain-containing 4 (BRD4) for Inducible Gene Expression

(2014) Xiangming Hu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts

(2014) S L Locatelli et al.   LEUKEMIA

Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP

(2014) O. S. Chao et al.   MOLECULAR CANCER RESEARCH

Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2

(2014) S. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

(2014) W. Fiskus et al.   MOLECULAR CANCER THERAPEUTICS

The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition

(2014) Junwei Shi et al.   MOLECULAR CELL

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones

(2014) Tomohiko Kanno et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

(2014) Joydeep Bhadury et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes

(2014) Stephen J. Atkinson et al.   MedChemComm

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

(2014) C Wong et al.   Cell Death & Disease

Panobinostat: a review of trial results and future prospects in multiple myeloma

(2014) Edward N Libby et al.   Expert Review of Hematology

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

(2013) B Groselj et al.   BRITISH JOURNAL OF CANCER

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer

(2013) Marije Slingerland et al.   CLINICAL THERAPEUTICS

Cancer Development, Progression, and Therapy: An Epigenetic Overview

(2013) Sibaji Sarkar et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma

(2013) TAKESHI YAMADA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2

(2013) G. J. Sabnis et al.   MOLECULAR CANCER THERAPEUTICS

Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling

(2013) K. T. Thurn et al.   MOLECULAR CANCER THERAPEUTICS

HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade

(2013) Y J Kim et al.   ONCOGENE

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

(2013) Anastasia Wyce et al.   PLoS One

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

(2013) M-C Chen et al.   Cell Death & Disease

Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

(2012) Panagis Filippakopoulos et al.   CELL

Targeting Epigenetic Readers in Cancer

(2012) Mark A. Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

(2012) Missak Haigentz et al.   ORAL ONCOLOGY

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

(2012) W. W. Lockwood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers

(2012) Günter Niegisch et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models

(2011) M. J. LaBonte et al.   CANCER RESEARCH

Functional Activation of the Estrogen Receptor-  and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole

(2011) G. J. Sabnis et al.   CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

(2011) Jacob E. Shabason et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

(2011) Daniel R. Premkumar et al.   MOLECULAR CARCINOGENESIS

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

(2011) B. B. Friday et al.   NEURO-ONCOLOGY

HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells

(2011) Chia-Wei Chou et al.   PLoS One

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

(2011) A. J. Christiansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells

(2011) Laura Bianchi et al.   PROTEOMICS

The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism

(2010) Daniela Buglio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Transcription elongation takes central stage: The P-TEFb connection

(2010) B. Matija Peterlin   CELL CYCLE

Nonhistone protein acetylation as cancer therapy targets

(2010) Brahma N Singh et al.   Expert Review of Anticancer Therapy

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

(2010) Anne Hansen Ree et al.   LANCET ONCOLOGY

Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001

(2010) Steffen Wedel et al.   LIFE SCIENCES

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

(2010) M. Namdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair

(2010) J.- H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor

(2010) Gaelle Diribarne et al.   RNA Biology

P-TEFb stimulates transcription elongation and pre-mRNA splicing through multilateral mechanisms

(2010) Tina Lenasi et al.   RNA Biology

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

(2009) L. R. Molife et al.   ANNALS OF ONCOLOGY

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

(2009) Melissa J LaBonte et al.   BMC Medical Genomics

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

(2009) P N Munster et al.   BRITISH JOURNAL OF CANCER

HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells

(2009) Xufeng Chen et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes

(2009) Zhibin Wang et al.   CELL

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

(2009) D. Mahalingam et al.   CLINICAL CANCER RESEARCH

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

(2009) G. Lopez et al.   CLINICAL CANCER RESEARCH

A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth

(2009) Christina Restall et al.   INTERNATIONAL JOURNAL OF CANCER

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

(2009) P Maiso et al.   LEUKEMIA

Cooperative binding of two acetylation marks on a histone tail by a single bromodomain

(2009) Jeanne Morinière et al.   NATURE

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

Combination Strategy Targeting the Hypoxia Inducible Factor-1  with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors

(2008) H. M.W. Verheul et al.   CLINICAL CANCER RESEARCH

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

(2008) T. H. Luu et al.   CLINICAL CANCER RESEARCH

Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer

(2008) Mari Björkman et al.   INTERNATIONAL JOURNAL OF CANCER

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

Regulation of protein turnover by acetyltransferases and deacetylases

(2007) Karin Sadoul et al.   BIOCHIMIE